GRI Bio, Inc. — Form 8-K Summary
Business Context and Reporting Period
GRI Bio, Inc. filed a Form 8-K dated November 22, 2023, reporting a Nasdaq continued-listing deficiency based on information in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2023. The company’s common stock trades on The Nasdaq Capital Market under the symbol GRI.
Key Financial and Listing Metrics
- Nasdaq Listing Rule 5550(b)(1) requires at least $2.5 million of stockholders’ equity for companies listed on the Nasdaq Capital Market with a market value of listed securities below $35 million and annual net income below $500,000.
- Nasdaq determined that the company did not meet the minimum stockholders’ equity requirement.
- The filing does not provide a clear value for the company’s stockholders’ equity, revenue, profit or loss, cash flow, margins, debt, or liquidity.
Material Changes Versus the Prior Comparable Period
The filing does not present comparative operating or financial results. The material development is the company’s receipt on November 22, 2023 of a Nasdaq notice stating that it was not in compliance with the minimum stockholders’ equity requirement.
Guidance, Outlook, Risks, and Contingencies
- The company had until January 6, 2024, or 45 calendar days from the notice, to submit a compliance plan to Nasdaq.
- If Nasdaq accepted the plan, its staff could grant an additional 180 calendar days from the notice date to regain compliance.
- There is no assurance that the compliance plan would be accepted or that the company would regain compliance.
- If the plan were rejected, the company’s common stock could become subject to delisting. The company could then appeal the determination to a Nasdaq Hearing Panel.
- The notice had no immediate effect on the company’s continued Nasdaq listing, provided that the company continued to satisfy other listing requirements.
- Key risks include failure to timely submit an acceptable compliance plan, failure to regain or maintain compliance, and potential delisting from Nasdaq.
Most Important Facts for Investors to Verify
- The company’s stockholders’ equity as of September 30, 2023 and the specific deficiency amount.
- Whether the company submitted a compliance plan by January 6, 2024 and whether Nasdaq accepted it.
- Any subsequent Nasdaq extension, hearing, appeal, delisting determination, or regained-compliance notice.
- The company’s cash position, financing needs, and ability to raise capital or otherwise increase stockholders’ equity.
- Compliance with all other Nasdaq continued-listing requirements.